Doug Ward is Chief Executive Officer of Personal Genome Diagnostics (PGDx), a Baltimore company empowering the fight against cancer by unlocking actionable information from the human genome. He has more than 25 years of experience within the diagnostic market, including leadership positions at top-tier molecular diagnostics and testing innovators such as Roche, GE Healthcare, Siemens Healthcare Diagnostics and Bayer Diagnostics. He joined PGDx in 2016 to lead the company to its next stage of growth, which is being realized through the development of a portfolio of regulated tissue-based and liquid biopsy genomic products for laboratories worldwide.

Adair Newhall Interviews Doug Ward, CEO of PGD - Part I

Adair Newhall Interviews Doug Ward, CEO of PGD - Part II

Adair Newhall Interviews Doug Ward, CEO of PGD - Part III

Adair Newhall Interviews Doug Ward, CEO of PGD - Part IV

Connect with Doug on LinkedIn

Edwin Warfield, CEO of citybizlist, conducts the CEO Interviews.

If you're interested in reaching CEOs, please contact edwin.warfield@citybuzz.co

Connect on LinkedIn

About Greenspring Associates
Established in 2000, Greenspring Associates provides venture capital solutions to a diverse group of institutions and individuals worldwide. Through a synergistic platform, the firm backs companies throughout their lifecycle, invests in established and emerging fund managers and serves as a liquidity provider through fund and direct secondary investments. An experienced investor in the cyber security, cloud and virtual networking verticals, Greenspring Associates has historically backed companies like Proofpoint (NYSE: PFPT) Cloudflare, Docker, Nutanix and Cologix. The firm currently manages over $6.3 billion in assets across multiple strategies. For more information on Greenspring Associates and its full investment portfolio, please visit www.greenspringassociates.com.